Partner

Articles & Insights / Residual Solvents

Residual Solvent Testing That Reflects the Process and the Product Matrix

Residual solvent control starts with knowing which solvents may remain and why. A suitable method then measures those solvents reliably in the actual material, with limits interpreted on the correct product and exposure basis.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Build the solvent history
  • Choose targets using evidence
  • Understand headspace partitioning

Build the solvent history

Review synthesis, extraction, purification, granulation, coating and other relevant operations. Include solvents introduced through purchased ingredients and recovered materials. A supplier statement should identify the relevant solvents and the basis for its conclusion, rather than refer vaguely to a product as solvent-free.

ICH Q3C(R9) addresses residual solvents in pharmaceutical substances, excipients and products within its scope. It distinguishes solvents to be avoided, solvents to be limited and those with lower toxic potential. Foods and nutraceutical extracts require their own permitted-solvent and residue assessment under the applicable regulations. Pharmaceutical classification does not establish that a solvent is permitted for a food application. R41R21

Choose targets using evidence

Testing every available solvent can create cost without resolving the actual risk. Conversely, a short generic panel can miss a solvent used in the process. Select the analytes using process history, impurity pathways and evidence of removal. Document why an earlier-stage solvent is no longer considered likely to remain where that conclusion is made.

Changes in supplier, drying conditions or solvent recovery can alter the assessment. A control strategy established for one extract or process should not be transferred automatically to another material with a different history.

Understand headspace partitioning

Headspace gas chromatography measures the volatile material entering the gas phase under defined conditions. The signal depends on temperature, equilibration time, vial fill, diluent and the sample matrix. Equal solvent concentrations in two different matrices can produce different responses if their partitioning differs.

The illustration illustrates the relationship between sample and headspace. The conceptual diagram does not imply that all solvent has evaporated or that the sample and vapour have the same concentration. Consistent preparation and demonstrated recovery are central to a useful quantitative procedure.

Explore the scienceResidual Solvents

The measured signal starts with partitioning

HeadspaceSample matrix
Sample matrix

Diluent, matrix and preparation influence the fraction entering the gas phase.

Conceptual explanation. No product result, acceptance criterion or universal regulatory sequence is established by this illustration.

Volatile analytes partition between the sample and headspace. Matrix, diluent, equilibration and preparation influence response; the drawing is conceptual and implies no measured partition coefficient.

Control volatility during preparation

Loss can occur before the vial is sealed through weighing, transfer or mixing. Evaluate the preparation sequence, vial closure and holding time, particularly for volatile targets. Q3C(R9) explicitly identifies solvent volatility as a validation consideration. R41

In a hypothetical recovery experiment, a spiked botanical matrix may initially give low response. Investigate whether the cause is evaporative loss, incomplete equilibration, matrix retention or interference. Increasing the incubation temperature may improve release but can also create degradation or artefacts, so the change requires evaluation rather than automatic acceptance.

Distinguish a screening result from a reportable result

Demonstrate selectivity for relevant solvent pairs and suitable performance around the decision level. Internal standards can help control some variation, but their suitability depends on behaviour relative to the analytes. Standard addition or matrix-matched approaches may be useful when justified by the matrix effect.

Loss on drying measures volatile mass loss under specified conditions. It does not identify individual solvents and can include water or other volatile components. Its use for residual solvent control is limited to justified circumstances under the applicable framework; it cannot distinguish a low concentration of a more hazardous solvent from a larger amount of water. R47

Make the report useful for quality decisions

State the analytes, method, units, reporting limits and material basis. Where exposure calculations are relevant, connect concentration to the maximum daily amount using consistent units. Distinguish a result below the quantitation limit from demonstrated absence. Report deviations or recovery limitations that affect interpretation.

Stabicon can support targeted solvent methods and testing plans that reflect the actual process and matrix, providing results that can be interpreted against the appropriate specification.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R41
    ICH Q3C R9 Impurities Guideline for Residual Solvents

    Final minor revision, 2024. Includes consideration of solvent volatility during analytical validation.

  2. R04
    ICH Q2 R2 Validation of Analytical Procedures

    Final guideline adopted November 2023. Analytical validation framework.

  3. R47
    USP General Chapter 731 Loss on Drying

    Official publisher preview. Measures volatile mass loss under specified conditions.

  4. R21
    FSSAI Health Supplements and Nutraceuticals Standards

    Official regulations portal. Verify current amendments, permitted ingredients, levels and category-specific requirements.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin